Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 109

1.

Intraperitoneal chemotherapy in ovarian cancer: a review of tolerance and efficacy.

Chan DL, Morris DL, Rao A, Chua TC.

Cancer Manag Res. 2012;4:413-22. doi: 10.2147/CMAR.S31070. Epub 2012 Nov 23.

2.

Optimal chemotherapy treatment for women with recurrent ovarian cancer.

Fung-Kee-Fung M, Oliver T, Elit L, Oza A, Hirte HW, Bryson P.

Curr Oncol. 2007 Oct;14(5):195-208.

3.

Survival benefit of adding Hyperthermic IntraPEritoneal Chemotherapy (HIPEC) at the different time-points of treatment of ovarian cancer: review of evidence.

Mulier S, Claes JP, Dierieck V, Amiel JO, Pahaut JP, Marcelis L, Bastin F, Vanderbeeken D, Finet C, Cran S, Velu T.

Curr Pharm Des. 2012;18(25):3793-803. Review.

PMID:
22591422
4.

Evaluation of extensive cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with advanced epithelial ovarian cancer.

Ansaloni L, Agnoletti V, Amadori A, Catena F, Cavaliere D, Coccolini F, De Iaco P, Di Battista M, Framarini M, Gazzotti F, Ghermandi C, Kopf B, Saponara M, Tauceri F, Vallicelli C, Verdecchia GM, Pinna AD.

Int J Gynecol Cancer. 2012 Jun;22(5):778-85. doi: 10.1097/IGC.0b013e31824d836c.

PMID:
22572845
5.

Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy as upfront therapy for advanced epithelial ovarian cancer: multi-institutional phase-II trial.

Deraco M, Kusamura S, Virzì S, Puccio F, Macrì A, Famulari C, Solazzo M, Bonomi S, Iusco DR, Baratti D.

Gynecol Oncol. 2011 Aug;122(2):215-20. doi: 10.1016/j.ygyno.2011.05.004. Epub 2011 Jun 12.

PMID:
21665254
6.

Secondary cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for recurrent epithelial ovarian cancer: a multi-institutional study.

Deraco M, Virzì S, Iusco DR, Puccio F, Macrì A, Famulari C, Solazzo M, Bonomi S, Grassi A, Baratti D, Kusamura S.

BJOG. 2012 Jun;119(7):800-9. doi: 10.1111/j.1471-0528.2011.03207.x.

7.

Cytoreductive surgery and modified heated intraoperative intraperitoneal chemotherapy (HIPEC) for advanced and recurrent ovarian cancer -- 12-year single center experience.

Pavlov MJ, Kovacevic PA, Ceranic MS, Stamenkovic AB, Ivanovic AM, Kecmanovic DM.

Eur J Surg Oncol. 2009 Nov;35(11):1186-91. doi: 10.1016/j.ejso.2009.03.004. Epub 2009 Apr 8.

PMID:
19356887
8.

Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) for persistent and recurrent advanced ovarian carcinoma: a multicenter, prospective study of 246 patients.

Bakrin N, Cotte E, Golfier F, Gilly FN, Freyer G, Helm W, Glehen O, Bereder JM.

Ann Surg Oncol. 2012 Dec;19(13):4052-8. doi: 10.1245/s10434-012-2510-4. Epub 2012 Jul 24.

PMID:
22825772
9.

Hyperthermic intraperitoneal chemotherapy (HIPEC) and cytoreductive surgery (CRS) in ovarian cancer: A systematic review and meta-analysis.

Huo YR, Richards A, Liauw W, Morris DL.

Eur J Surg Oncol. 2015 Dec;41(12):1578-89. doi: 10.1016/j.ejso.2015.08.172. Epub 2015 Sep 25. Review.

PMID:
26453145
10.

A critical appraisal of hyperthermic intraperitoneal chemotherapy (HIPEC) in the treatment of advanced and recurrent ovarian cancer.

Chiva LM, Gonzalez-Martin A.

Gynecol Oncol. 2015 Jan;136(1):130-5. doi: 10.1016/j.ygyno.2014.11.072. Epub 2014 Nov 28.

PMID:
25434634
11.

Iterative procedures combining cytoreductive surgery with hyperthermic intraperitoneal chemotherapy for peritoneal recurrence: postoperative and long-term results.

Golse N, Bakrin N, Passot G, Mohamed F, Vaudoyer D, Gilly FN, Glehen O, Cotte E.

J Surg Oncol. 2012 Aug 1;106(2):197-203. doi: 10.1002/jso.23062. Epub 2012 Feb 13.

PMID:
22331814
12.

A systematic overview of chemotherapy effects in ovarian cancer.

Högberg T, Glimelius B, Nygren P; SBU-group. Swedish Council of Technology Assessment in Health Care.

Acta Oncol. 2001;40(2-3):340-60. Review.

PMID:
11441940
13.

Cytoreductive surgery (peritonectomy procedures) combined with hyperthermic intraperitoneal chemotherapy (HIPEC) in the treatment of diffuse peritoneal carcinomatosis from ovarian cancer.

Di Giorgio A, Naticchioni E, Biacchi D, Sibio S, Accarpio F, Rocco M, Tarquini S, Di Seri M, Ciardi A, Montruccoli D, Sammartino P.

Cancer. 2008 Jul 15;113(2):315-25. doi: 10.1002/cncr.23553.

14.

[Secondary debulking surgery and intraperitoneal chemotherapy in advanced or recurrent epithelial ovarian cancer].

Plaisant N, Quenet F, Fabbro M, Gourgou S, Gutowski M, Saint-Aubert B, Rouanet P.

Gynecol Obstet Fertil. 2004 May;32(5):391-7. French.

PMID:
15177208
15.

[Feasibility, morbidity and survival of surgery combined with HIPEC in the management of recurrent ovarian cancer].

Furet E, Chéreau E, Lambaudie E, Bannier M, Houvenaeghel G.

Gynecol Obstet Fertil. 2013 Sep;41(9):493-8. doi: 10.1016/j.gyobfe.2013.07.011. Epub 2013 Aug 21. French.

PMID:
23972918
16.

Intraperitoneal chemotherapy for recurrent epithelial ovarian cancer is feasible with high completion rates, low complications, and acceptable patient outcomes.

Skaznik-Wikiel ME, Lesnock JL, McBee WC, Beriwal S, Zorn KK, Richard SD, Krivak TC, Edwards RP.

Int J Gynecol Cancer. 2012 Feb;22(2):232-7. doi: 10.1097/IGC.0b013e318234f833.

PMID:
22080886
17.

Early- and long-term outcome data of patients with pseudomyxoma peritonei from appendiceal origin treated by a strategy of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.

Chua TC, Moran BJ, Sugarbaker PH, Levine EA, Glehen O, Gilly FN, Baratti D, Deraco M, Elias D, Sardi A, Liauw W, Yan TD, Barrios P, Gómez Portilla A, de Hingh IH, Ceelen WP, Pelz JO, Piso P, González-Moreno S, Van Der Speeten K, Morris DL.

J Clin Oncol. 2012 Jul 10;30(20):2449-56. doi: 10.1200/JCO.2011.39.7166. Epub 2012 May 21.

PMID:
22614976
18.

Cytoreductive surgery and intraperitoneal chemotherapy for colorectal peritoneal carcinomatosis: prognosis and treatment of recurrences in a cohort study.

Cashin PH, Graf W, Nygren P, Mahteme H.

Eur J Surg Oncol. 2012 Jun;38(6):509-15. doi: 10.1016/j.ejso.2012.03.001. Epub 2012 Apr 3.

PMID:
22475555
19.
20.

Secondary cytoreduction plus oxaliplatin-based HIPEC in platinum-sensitive recurrent ovarian cancer patients: a pilot study.

Fagotti A, Paris I, Grimolizzi F, Fanfani F, Vizzielli G, Naldini A, Scambia G.

Gynecol Oncol. 2009 Jun;113(3):335-40. doi: 10.1016/j.ygyno.2009.03.004. Epub 2009 Apr 5.

PMID:
19345401

Supplemental Content

Support Center